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Background: The aim of the study was to evaluate predictive and prognostic significance of
microtubule-associated protein Tau in epithelial ovarian cancer (EOC) patients treated with paclitaxel and
platinum-based chemotherapy.
Methods: 74 patients with EOC (stage I-IV) who underwent cytoreductive surgery followed by standard paclitaxel/
platinum chemotherapy were included in the retrospective analysis. Their formalin-fixed, paraffin-embedded tissue
specimens were immunohistochemically stained for Tau protein, using semi-quantitative DAKO test. Tau expression
was acknowledged as negative (0 and 1+) or positive (2+ and 3+). The correlation between Tau expression,
progression free survival (PFS) and overall survival (OS) was evaluated. Statistical analysis included Kaplan-Meyer
estimator, long rank test, Mann Whitney test and Cox proportional hazards model.
Results: 25.7% (19/74) and 74.3% (55/74) of the patients were classified as Tau-negative and Tau-positive,
respectively. Median PFS was 28.7 months for Tau-negative group and 15.9 months for Tau-positive group
(p = 0.0355). In the univariate analysis 3-year OS in Tau-negative and Tau-positive groups was 80.2% and 52.4%,
respectively (p = 0.0198). Low expression of protein Tau was associated with better OS, whereas an advanced stage
at diagnosis, suboptimal surgery, serous histological type and resistance to first line chemotherapy were each
correlated with worse OS (p <0,05). In multivariate analysis only resistance to first line chemotherapy remained
significant (HR 22.59; 95% CI, 8.71-58.55; p <0.0001).
Conclusions: Negative tau protein seems to be both good prognostic factor and a predictor of response to
paclitaxel/platinum-based chemotherapy in EOC patients.
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Ovarian cancer remains leading cause of death among
patients with different gynecological neoplasms. Al-
though majority of the patients respond to the primary
treatment with debulking surgery followed by paclitaxel
and platinum-based chemotherapy, many of them ex-
perience relapse of the disease within few years after
first-line therapy.* Correspondence: smoterm@wp.pl
1Oncology Department, Military Institute of Health Services in Warsaw,
Szaserów Street 128, Warszawa 04-141, Poland
Full list of author information is available at the end of the article
© 2013 Smoter et al.; licensee BioMed Central
Commons Attribution License (http://creativec
reproduction in any medium, provided the orPlatinum compounds introduction to the ovarian can-
cer treatment was a corner stone in the therapy of this
malignancy. Paclitaxel addition to platinum improves
the results of chemotherapy [1,2]. Nevertheless about
one quarter of the patients does not respond to the the-
rapy and those who initially benefit from the treatment
incline to experience disease recurrence.
There are no molecular agents known to predict the
response to the chemotherapy in ovarian cancer as well
as patients’ outcome. Revelation of such markers could
result in a more effective patient selection to the certain
regimens and development of tailored chemotherapy in
ovarian cancer.Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Patient characteristics
Median age, range (years) 54 (31–73)
Performance status (ECOG scale)
• 0 12.2% (9/74)
• 1 81.1% (60/74)
• 2 6.7% (5/74)
Histologic cell type
• Serous 50% (37/74)
• Endometrioid 22.97% (17/74)
• Mucinous 6.76% (5/74)
• Clear cell 4.05% (3/74)
• Mixed 13.51% (10/74)
• Undifferentiated 1.35% (1/74)
• Others 1.35% (1/74)
FIGO stage at diagnosis
▪ I 8.1% (6/74)
▪ II 12.2% (9/74)
▪ III 58.1% (43/74)
▪ IV 21.6% (16/74)
Primary surgery
▪ Radical 16.2% (12/74)
▪ Optimal debulking 48.6% (36/74)
▪ Suboptimal debulking 35.1% (26/74)
Grade (G)
▪ 1 and 2 41.9% (31/74)
▪ 3 and unknown 58.1% (43/74)
Platinum sensitivity
Sensitive (>6 months) 64.9% (48/74)
Resistant (<6 months) 35.1% (26/74)
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has been identified as a potential marker of response to
paclitaxel in breast cancer. Tau protein (50–64 kD), a
product of gene located in chromosome 17 (17q21) shows
the ability of combining to beta-tubulin. It may bind to
the exterior as well as to the interior microtubules surface,
in the same binding site as paclitaxel, and consequently
compete with this drug [3,4]. The loop of beta tubulin
combined to Tau stabilizes microtubules in similar way as
paclitaxel, but with a smaller affinity and greater revers-
ibility [5]. Overexpression of Tau protein leads to increase
of polymerization and at the same time reduces cells’ flexi-
bility [6].
Six isoforms of Tau protein occur in nature and are di-
vided into two groups, depending on the number of do-
mains combined to tubulin. Tau-3L, Tau-3S and Tau-3
belong to group 3R and connects with tubulin by three do-
mains, while Tau-4L, Tau-4S and Tau-4 (group 4R) uses four
domains to bind to tubulin [7].
Tau protein activity and affinity to microtubules is reg-
ulated in phosphorylation processes by serine threonine
kinases. Phosphorylation of certain places for example
serine 262 or 396 is related to reduction of binding
of Tau to microtubules [7]. At the same time,
overphosphorylation of this protein leads to neurofibril-
lary degeneration and is suggested to have an important
impact on pathogenesis of neurodegenerative diseases,
which clinically demonstrate with the limitation of
cognitive functions, including Alzheimer’s or Pick’s dis-
eases [7].
Predictive or prognostic value of protein Tau in ovarian
cancer has not been yet established. We aimed to determine
the relevance of Tau expression in this malignancy. We have
investigated retrospectively the correlation between immu-
nohistochemical expression of protein Tau in the primary
tumors and progression free survival (PFS) as well as overall
survival (OS) in epithelial ovarian cancer patients treated




We included in our study consecutive patients treated in
our site between March 2001 and December 2007, who
fulfilled following inclusion criteria:
1) histologically confirmed epithelial ovarian cancer
International Federation of Gynaecology and
Obstetrics (FIGO) stage IC-IV,
2) history of debulking surgery followed by first-line
chemotherapy regimen: paclitaxel (135 mg/m2) with
cisplatin (75 mg/m2) or paclitaxel (175 mg/m2) with
carboplatin (AUC6), administered every 3 weeks for
6 cycles,3) accessibility of primary tumor specimens and full
medical data.
Among 132 patients in our database, 74 were eligible.
Remaining 58 patients were excluded from the analysis
due to inaccessibility of primary tumour specimens (48),
deficiency in clinical data (5) or diagnosis of concomi-
tant malignancy (5). Table 1 summarizes clinical charac-
teristics of the patients included in the analysis. Median
age in the study group was 54 years (range 31–73).
79,7% of the patients was diagnosed at advanced FIGO
stage (III-IV). Half of the patients had diagnosed serous
type of ovarian cancer 64.9% of the group were sensitive
to chemotherapy.
Local Research Ethics Committee approved the study
on 19th of March 2008 (number 11/2008). Primary
tumor specimens of the patients included in the analysis
were immunohistochemically stained for tau protein. Pa-
tients’ data: response to first-line chemotherapy
according to RECIST criteria, PFS, OS were obtained
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dian observation period was 25 months (95% CI, 24–32).
Immunochemistry
Material was obtained from primary tumors of 74 pa-
tients and immunohistochemically stained for Tau pro-
tein. In bilateral ovarian cancer cases (41/74), both
tumors were stained. Formalin-fixed, paraffin-embedded
5-μm sections of ovarian cancer were incubated with
anti-Tau polyclonal rabbit antibody that recognizes all
isoforms of human Tau irrespectively of its phosphoryl-
ation status (1:100 dilution; code A 0024; DAKO
Cytomation) for 30 minutes in room temperature. Anti-
rabbit horseradish peroxidase-labeled secondary anti-
body was used to generate signal (code K 4002; DAKO
Envision TM+ System). Normal ovarian epithelium de-
rived from 51-year-old patient who had underwent sur-
gery due to benign ovarian cyst was used as an external
positive control. Omission of primary antibody served as
a negative control. Specimens were assessed by means of
light microscope with 20 × magnification lens. Tau stain-
ing of tumor cells was scored according to Rouzier et al.
[4] with the authors’ modification as follows: IHC score
0 – no staining; 1+ − poor focal staining or very poor
diffuse staining (less intense than normal ovarian epithe-
lium); 2+ average diffuse staining (similar to normal
ovarian epithelium) or strong staining (more intense
than normal ovarian epithelium) in less than 25% cells; 3
+ strong staining in 25% of tumors cells or moreFigure 1 Tau protein expression by IHC (a-d). Tau 0 (a) - completely ne
intense staining of fallopian tube epithelium on the right (double arrows) s
(b) Adenocarcinoma cells with weak focal expression of Tau protein (magn
similar to pattern of staining of superficial ovarian epithelium (arrow) (mag
cytoplasmatic granules.(Figure 1). Tau expression was acknowledged as negative
(0 and 1+) or positive (2+ and 3+). This dichotomization
of staining results was determined by using staining in-
tensity of normal epithelial cells as a reference. In case
of bilateral ovarian cancer the staining results from both
ovaries were averaged. In case of averaged results, they
were acknowledged as negative (0–1,5) and positive (2–
3). Slides were scored without knowledge of the clinical
outcome.Statistical analysis
Statistical analysis included descriptive statistics with de-
termination of minimal and maximal values, means and
medians, with 95% confidence interval (CI) for particular
variables. The correlation between Tau expression and
clinical parameters was assessed by X2 test. PFS was de-
fined as the time from diagnosis until disease recurrence
or death, while OS was the time from diagnosis until
death or cut-off point which was 15 Dec 2009.
Analysis of PFS and OS was done by means of Kaplan-
Meier method. Univariate analyses of variables influen-
cing PFS or OS was performed by log-rank test, which
identified preliminary list of significant factors. Multi-
variate analyses of PFS and OS were performed by Cox
proportional-hazard regression using the forward step-
wise method; all variables found to be significant in the
univariate analysis were included in the multivariate
analysis.gative staining with anti-Tau antibody in tumor cells (left). Moderately
erves as internal positive control (magnification 200×). Tau 1+
ification 200×). Tau 2+ (c) Moderately intense staining of tumor cells
nification 200×). Tau 3+ (d) Intense and diffuse staining as dark
Smoter et al. Journal of Experimental & Clinical Cancer Research 2013, 32:25 Page 4 of 8
http://www.jeccr.com/content/32/1/25Statistical significance was defined as a probability
level less than 0.05. Statistical calculation was performed
using the STATISTICA for Windows Version 7.0
software.Results
Tau expression in ovarian cancer
According to the best knowledge of the authors, in our
study Tau expression was evaluated in ovarian cancer
for the first time. Among 74 patients included in the
analysis, 74.3% (n=55) were Tau-positive and 25.7%
(n=19) were Tau-negative.Figure 2 Progression free survival by tau expression.Association between Tau expression and PFS
Univariate analysis revealed following clinical parameters
correlated with PFS: FIGO stage at diagnosis (p=0.004),
ovarian cancer type (serous vs. others; p=0.0202), re-
sidual tumor size after debulking surgery (p=0.005) and
tau expression level (p=0.0355). Age, performance status
and tumor grade were not correlated with PFS. The re-
sults are presented in Table 2 and Figure 2.
Multivariate analysis showed that among factors corre-
lated with PFS in univariate analysis, only residual tumor
size occurred as independently associated with PFS
(p=0.0002, HR – 2.84) (Table 3).Table 2 Univariate analysis of PFS ( log-rank test)
Clinical parameter n (% ) Median (months) P value
Age
0.3447○ < 65 60 (81.1%) 17.4
○ > 65 14 (18.9%) 20.0
FIGO stage at diagnosis
○ Early (I,II) 15 (20.3%) 76.3%†
0.0040*
○ Advanced (III,IV) 59 (79.7%) 33.3%†
Histopathologic cell type
○ serous 37 (50%) 16.8
0.0202*
○ others 37 (50%) 31.5
Residual tumor size
0.0005*○ <1 cm 48 (64.9%) 28.3
○ > 1 cm 26 (35.1%) 8.9
Performance status (ECOG)
0.1388○ 0-1 69 (93.2%) 20.0
○ 2 5 (6.7%) 17.4
Tumor grade
0.4788○ G1,G2 31 (41.9%) 26.7
○ G3, unknown 43 (58.1%) 16.6
Tau expression
0.0355*○ negative 19 (25.6%) 28.7
○ positive 55 (74.3%) 15.9
†− if median was not achieved, the results were described as a percentage of
patients with 2 years PFS *- statistical significance.Association between Tau expression and OS
Clinical parameters correlated with OS were identified
in univariate analysis and presented in Table 4. Statistical
significance was achieved in following factors: FIGO
stage at diagnosis (p=0.0168), ovarian cancer type
(p=0.0166), residual tumor size (p=0.0026), tau expres-
sion status (p=0.0198) (Figure 3) and sensitivity to first-
line chemotherapy (p<0.0001). Age, performance status
and tumor grade were not correlated with OS.
In multivariate analysis only sensitivity to first-line




























Abbreviations: HR- hazard ratio, NS – not significant.
Table 4 Univariate analysis of OS correlation with clinical parameters (log-rank test)
Clinical parameter n (% ) Median (months) P value
Age 0.5287
o < 65 60 (81.1%) 41.8
o > 65 14 (18.9%) 36.6
FIGO stage at diagnosis
o Early (I,II) 15 (20.3%) 88.2%†
0.0168*
o Advanced (III,IV) 59 (79.7%) 50.5%†
Histopathologic cell type
o serous 37 (50%) 33.4
0.0166*
o others 37 (50%) 54.8
Residual tumor size
o <1 cm 48 (64.9%) 50.2
0.0026*
o > 1 cm 26 (35.1%) 22.6
Performance status (ECOG)
o 0-1 69 (93.2%) 42.9
0.3461
o 5 (6.7%) 5 (6.7%) 15.1
Tumor grade
o G1,G2 31 (41.9%) 49.0
0.2099
o G3, unknown 43 (58.1%) 30.0
Sensitivity to first-line chemotherapy
o Resistant (<6 months) 26 (35.1%) 4.6%†
<0.0001*
o Sensitive (>6 months) 48 (64.9%) 87.8%†
Tau expression
o negative 19(25.6%) 80.2%†
0.0198*
o positive 55(79.3%) 52.4%†
†− if median was not achieved, the results were described as a percentage of patients with 3-year OS.
*- statistical significance.
Figure 3 Overall survival by tau expression.
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OS (Table 5).
Association between Tau expression and response to
chemotherapy in patients with measurable disease
Among 46 patients with measurable target lesions, 11
(23.9%) were assessed as Tau-negative and 35 (76.1%) as
Tau-positive. Proportion of objective response (OR) was
higher in Tau-negative group (90.9%) compared with
Tau-positive group (54.3%), with statistical significance
(p=0.0299). The results are demonstrated in Table 6.
Discussion
Currently, the most effective chemotherapy in ovarian
cancer, recognized as a gold standard is platinum
analogue combined with paclitaxel. About 70% of the
patients respond to this regimen. The others potentially
could benefit from different drugs. However, no predict-
ive factors are known in ovarian cancer.
As far as we are concerned, in our study Tau protein
was assessed in the tissues of ovarian cancer for the first
Table 5 Multivariate analysis of OS association with
clinical parameters
Clinical parameter Multivariate analysis
HR (95% CI) P value
Tau expression NS NS
▪ negative
▪ positive
FIGO stage at diagnosis NS NS
○ Early (I,II)
○ Advanced (III,IV)
Histopathologic cell type NS NS
○ serous
○ others
Residual tumor size NS NS
○ <1 cm
○ > 1 cm
Sensitivity to first-line
chemotherapy
22.59; 95% CI, 8.71-
58.55
<0.0001
○ Resistant (<6 months)
○ Sensitive (>6 months)
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ity of the patients was acknowledged as Tau-positive
(74.3%), while 25.6% of the patients was Tau-negative.
The results differ from those achieved in other studies.
Rouzier et al. recognized 52% of the breast cancer pa-
tients as Tau-negative [4]. Similar proportion (57% of
Tau-negative) was demonstrated by Pusztai et al. [8] 30%
of the patients with gastric cancer in Mimori et al. study
was identified as Tau-negative [9]. Obtained findings in-
dicate that Tau protein expression might differ among
cancer sites.
In our study, Tau-negative status in primary tumor of
ovarian cancer was identified as a predictive factor for
paclitaxel-containing chemotherapy. Both groups seem
to be well balanced regarding to age, FIGO stage, histo-
logical type, performance status and grade (Table 7) so itTable 6 Association between Tau expression and response to





Negative Tau expression (n=11) P
n %






Abbreviations: OR – objective response, CR – complete response, PR- partial respondoes not seem that there were any biases in this field al-
though it necessary to remember that our study was
conducted retrospectivly, so its value is limited. In uni-
variate analysis median PFS was 12.8 months longer in
Tau-negative group (p=0.0355). Among 46 patients with
measurable target lesions, those qualified as Tau-
negative achieved statistically significant more objective
responses according to RECIST criteria in comparison to
patients with Tau-positive ovarian cancers (90.9% and
54.3% respectively; p=0.0299).
Thus, negative status of Tau in primary tumor of
ovarian cancer is associated with better efficacy of
chemotherapy. It may result from paclitaxel’s action,
competitive to Tau protein. Paclitaxel binds beta-tubulin
on microtubule’s inner surface, in the same point as Tau
protein [5]. It leads to inhibition of depolimerisation
process, interferes with spindle function and hinders cell
division [6]. Presence of Tau protein on the microtu-
bules’ surface creates difficulties in paclitaxel combining
to these structures. Low Tau expression may result in
better paclitaxel connection with microtubules and more
effective chemotherapy action, expressed in higher ob-
jective responses rate and better PFS.
So far, predictive role of Tau expression was assessed
in breast and gastric cancers. Low Tau protein expres-
sion (Rouzier) or low Tau-mRNA (Andre) was associated
with statistically significant more frequent achievement
of complete response (CR) to paclitaxel in breast cancer.
Similarly, in the study of Tanaki et al. [10], significantly
more Tau-negative patients with metastatic breast cancer
benefited from paclitaxel therapy, compered with Tau-
positive group of patients.
However, about half of Tau-negative patients receiving
paclitaxel was not sensitive to this chemotherapy[4,10].
The other mechanisms of resistance to paclitaxel: tubu-
lin mutations, different tubulin isoforms, overexpression
of multidrug resistance proteins or bcl-2 might be re-
sponsible for this phenomenon. Identification of single
factor (in our case Tau protein expression) might not be
sufficient to provide selection to the certain treatment.chemotherapy in patients with measurable target lesions
ositive Tau expression (n=35) Mann – Whitney test U









se, SD – stable disease, PD – progression disease.
Table 7 Clinicopathologic features in ovarian cancer
patients according to Tau expression






o < 65 16 44 p=
,8496*o ≥ 65 4 10
FIGO stage at
diagnosis
o Early (I,II) 7 10 p=
,1345o Advanced (III,IV) 13 44
Histopathologic cell
type
o Serous 8 29 p=
,2951o others 12 25
Performance status
(ECOG)
o 0-1 19 50 p=
,8768*o 2 1 4
Tumor grade
o G1,G2 12 19
p=
,0547o G3, unknown 8 35
Abbreviations: p- Probability values calculated by the Chi-square test,
* p- Values calculated by the Chi-square test with Yates correction.
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Tau siRNA in paclitaxel-resistant cell lines caused in-
crease of their sensitivity to this drug, inhibition of Tau
protein may enhance paclitaxel activity [4].
Predictive value of Tau protein was not confirmed in
some studies [8,11-13]. Statistically non-significant trend
of increased sensitivity to paclitaxel was observed in
Tau-negative ER(−) breast cancer patients [11]. ER(−)
and ER(+) patients should be analyzed separately. Func-
tion of Tau gene is regulated by estrogens and expres-
sion of Tau protein in vitro might be induced by these
hormones as well as tamoxifen. Additionally, predictive
value of low Tau expression for paclitaxel therapy
was confirmed in gastric cancer, potentially hormone-
independent malignancy [9].
The results of the recent study of Fekete et al. reveal a
possible prediction of relapse-free survival by Tau gene
expression by TaqMan Real Time Polymerase Chain Re-
action (RT-PCR) and relapse-free survival [14].
Prognostic value of Tau expression in ovarian cancer
patients treated with paclitaxel and platinum-based
chemotherapy was revealed in univariate analysis of our
study. Percentage of patients achieving 3-year overall
survival was significantly higher in Tau-negative group
(80.2%) than in Tau-positive (52.4%).
Our results differ from those obtained in the studies
on breast cancer, where co-expression of Tau protein
and estrogen receptor was considered as good prognos-
tic factor [8,11,15]. This divergence might be caused byTau significance evaluation in different cancer sites.
Hormone-dependent breast cancer is associated with
good prognosis and chemo resistance. Tau genes are reg-
ulated by estrogens and tamoxifen so Tau protein ex-
pression is associated with hormones. On the other
hand, in ER-negative breast cancer patients group prog-
nostic value of Tau protein was not confirmed. In other
study prognostic value of Tau protein in breast cancer
was not observed [13].
The only independent parameter significantly influen-
cing on OS in multivariate analysis was sensitivity to
first-line chemotherapy (HR 22.59; p<0.0001), defined as
no progression or recurrent disease in 6 months from
the end of treatment. The aim of adjuvant chemotherapy
is prolongation of OS as well as PFS. The effect is pos-
sible to achieve if malignancy is prone to drugs. Thus,
chemosensitivity is a good prognostic factor.
Conclusions
Many studies confirm prognostic value of time duration
between chemotherapy ending and disease progression
in ovarian cancer [16-18]. Extension of this period might
be caused by tumor susceptibility to cytostatics as well
as maximal cytoreduction during surgery.
Mechanisms affecting chemosensitivity are complex.
Tau expression is a single factor, influencing sensitivity
to paclitaxel. Platinum analogue (the other component
of standard regimen in ovarian cancer) effectiveness is
modified by numerous factors such as epigenic changes
in cancer cells, expression of multidrug resistance pro-
teins (for example: P-gp, MRP1, MRP2, LRP), p53 gene
mutations and GST-pi increase [19]. The processes are
intricate, thus identification of single factors seems to be
complicated, especially in polichemotherapy.
Better response to paclitaxel related to negative status
of Tau protein in primary tumors in ovarian cancer is
conducive to extension of PFS, and therefore to the im-
provement of prognosis in ovarian cancer patients. Al-
though sample size in our analysis was not great and the
data were evaluated retrospectively, the results of our
study may direct successive researches in ovarian cancer.
Significance of Tau protein expression requires evalu-
ation in prospective studies with larger group of pa-
tients, including assessment of the other predictive and
prognostic parameters in paclitaxel and platinum-based
chemotherapy.
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